Bridged Nucleic Acids Reloaded

Oligonucleotides are key compounds widely used for research, diagnostics, and therapeutics. The rapid increase in oligonucleotide-based applications, together with the progress in nucleic acids research, has led to the design of nucleotide analogs that, when part of these oligomers, enhance their efficiency, bioavailability, or stability. One of the most useful nucleotide analogs is the first-generation bridged nucleic acids (BNA), also known as locked nucleic acids (LNA), which were used in combination with ribonucleotides, deoxyribonucleotides, or other analogs to construct oligomers with diverse applications. However, there is still room to improve their efficiency, bioavailability, stability, and, importantly, toxicity. A second-generation BNA, BNANC (2′-O,4′-aminoethylene bridged nucleic acid), has been recently made available. Oligomers containing these analogs not only showed less toxicity when compared to LNA-containing compounds but, in some cases, also exhibited higher specificity. Although there are still few applications where BNANC-containing compounds have been researched, the promising results warrant more effort in incorporating these analogs for other applications. Furthermore, newer BNA compounds will be introduced in the near future, offering great hope to oligonucleotide-based fields of research and applications.

[1]  David E. Housman,et al.  Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member , 1992, Cell.

[2]  M. Gait,et al.  miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. , 2007, RNA.

[3]  Michael Petersen,et al.  LNA: a versatile tool for therapeutics and genomics. , 2003, Trends in biotechnology.

[4]  R. Bonomo,et al.  Exploring Additional Dimensions of Complexity in Inhibitor Design for Serine β-Lactamases: Mechanistic and Intra- and Inter-molecular Chemistry Approaches , 2018, Front. Microbiol..

[5]  S. Zeuzem,et al.  Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. , 2014, Antiviral research.

[6]  M. Sakai,et al.  Improvements in Bacterial Primers to Enhance Selective SSU rRNA Gene Amplification of Plant-associated Bacteria by Applying the LNA Oligonucleotide-PCR Clamping Technique , 2018, Microbes and environments.

[7]  V. Erdmann,et al.  Design of antisense oligonucleotides stabilized by locked nucleic acids. , 2002, Nucleic acids research.

[8]  Rob Willemsen,et al.  Microsatellite repeat instability and neurological disease , 2009, BioEssays : news and reviews in molecular, cellular and developmental biology.

[9]  Dilay Hazal Ayhan,et al.  Sequence-Specific Targeting of Bacterial Resistance Genes Increases Antibiotic Efficacy , 2016, PLoS biology.

[10]  A. Burdick,et al.  Comparison of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides: evidence of distinct pathways contributing to non-target mediated toxicity in mice. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.

[11]  D. Segal,et al.  How specific is CRISPR/Cas9 really? , 2015, Current opinion in chemical biology.

[12]  R. Barrangou,et al.  Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria , 2012, Proceedings of the National Academy of Sciences.

[13]  A. Pavlícek,et al.  Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial , 2017, The Lancet.

[14]  E. Nanba,et al.  [Myotonic dystrophy]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.

[15]  T. Cooper,et al.  Pathogenic mechanisms of myotonic dystrophy. , 2009, Biochemical Society transactions.

[16]  T. Chevassut,et al.  Rapid detection of DNMT3A R882 codon mutations allows early identification of poor risk patients with acute myeloid leukemia , 2013, Leukemia & lymphoma.

[17]  Alex Toftgaard Nielsen,et al.  Single nucleotide polymorphism genotyping using locked nucleic acid (LNA™) , 2003, Expert review of molecular diagnostics.

[18]  N. Seidah,et al.  A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo , 2010, PloS one.

[19]  Peter E. Nielsen Peptide Nucleic Acids (PNA) in Chemical Biology and Drug Discovery , 2010, Chemistry & biodiversity.

[20]  P. Nielsen,et al.  Nucleobase-modified antisense oligonucleotides containing 5-(phenyltriazol)-2′-deoxyuridine nucleotides induce exon-skipping in vitro , 2017 .

[21]  Israel Steinfeld,et al.  Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells , 2015, Nature Biotechnology.

[22]  T. Kasuya,et al.  Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides , 2016, Scientific Reports.

[23]  Xiaoxia Qi,et al.  Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA , 2007, Science.

[24]  K. Sobczak,et al.  Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy , 2015, Nucleic acids research.

[25]  J. Burnett,et al.  RNA-based therapeutics: current progress and future prospects. , 2012, Chemistry & biology.

[26]  M. Tolmasky,et al.  Assessment of configurations and chemistries of bridged nucleic acids-containing oligomers as external guide sequences: a methodology for inhibition of expression of antibiotic resistance genes , 2016, Biology methods & protocols.

[27]  G. Church,et al.  Cas9 as a versatile tool for engineering biology , 2013, Nature Methods.

[28]  Y. Hari,et al.  A bridged nucleic acid, 2′,4′-BNACOC: synthesis of fully modified oligonucleotides bearing thymine, 5-methylcytosine, adenine and guanine 2′,4′-BNACOC monomers and RNA-selective nucleic-acid recognition , 2009, Nucleic acids research.

[29]  H. Kantarjian,et al.  Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis. , 2012, The Journal of molecular diagnostics : JMD.

[30]  J. Wengel,et al.  A structure-activity study of the inhibition of HIV-1 Tat-dependent trans-activation by mixmer 2'-O-methyl oligoribonucleotides containing locked nucleic acid (LNA), alpha-L-LNA, or 2'-thio-LNA residues. , 2003, Oligonucleotides.

[31]  S. Altman,et al.  External guide sequences for an RNA enzyme. , 1990, Science.

[32]  Fritz Eckstein,et al.  Phosphorothioates, essential components of therapeutic oligonucleotides. , 2014, Nucleic acid therapeutics.

[33]  T. Ikegami,et al.  Characterization of DNA-binding activity in the N-terminal domain of the DNA methyltransferase Dnmt3a. , 2011, The Biochemical journal.

[34]  Marcel Mettlen,et al.  Dissecting dynamin's role in clathrin-mediated endocytosis. , 2009, Biochemical Society transactions.

[35]  E. Gunić,et al.  Conformationally locked nucleosides. Synthesis and hybridization properties of oligodeoxynucleotides containing 2',4'-C-bridged 2'-deoxynucleosides. , 1999, Bioorganic & medicinal chemistry letters.

[36]  Kutubuddin A Molla,et al.  CRISPR/Cas-Mediated Base Editing: Technical Considerations and Practical Applications. , 2019, Trends in biotechnology.

[37]  G. Storz,et al.  Bacterial antisense RNAs: how many are there, and what are they doing? , 2010, Annual review of genetics.

[38]  J. Wengel,et al.  MicroRNA therapeutics: design of single-stranded miR-216b mimics to target KRAS in pancreatic cancer cells , 2018, RNA biology.

[39]  Jeffry D. Sander,et al.  CRISPR-Cas systems for editing, regulating and targeting genomes , 2014, Nature Biotechnology.

[40]  Xiao-Qing Yuan,et al.  DNMT3A R882 Mutations Predict a Poor Prognosis in AML , 2016, Medicine.

[41]  C. Wahlestedt,et al.  Locked nucleic acid containing antisense oligonucleotides enhance inhibition of HIV‐1 genome dimerization and inhibit virus replication , 2004, FEBS letters.

[42]  K. Miyashita,et al.  Highly stable pyrimidine-motif triplex formation at physiological pH values by a bridged nucleic acid analogue. , 2007, Angewandte Chemie.

[43]  Poul Nielsen,et al.  LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition , 1998 .

[44]  R. Persson,et al.  Locked nucleic acid: modality, diversity, and drug discovery. , 2018, Drug discovery today.

[45]  Peixuan Guo,et al.  RNA Micelles for the Systemic Delivery of Anti-miRNA for Cancer Targeting and Inhibition without Ligand. , 2018, ACS nano.

[46]  G. Lambert,et al.  PCSK9: from biology to clinical applications. , 2019, Pathology.

[47]  Jinho Park,et al.  Incorporation of bridged nucleic acids into CRISPR RNAs improves Cas9 endonuclease specificity , 2018, Nature Communications.

[48]  M. Caligiuri,et al.  Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  T. Cooper,et al.  BNANC Gapmers Revert Splicing and Reduce RNA Foci with Low Toxicity in Myotonic Dystrophy Cells. , 2017, ACS chemical biology.

[50]  H. Soifer,et al.  Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents , 2009, Nucleic acids research.

[51]  Ning Wang,et al.  Reversion of antibiotic resistance by inhibiting mecA in clinical methicillin-resistant Staphylococci by antisense phosphorothioate oligonucleotide , 2014, The Journal of Antibiotics.

[52]  B. Geller,et al.  Antisense antimicrobial therapeutics , 2016, Current Opinion in Microbiology.

[53]  R. Bonomo,et al.  The Continuing Challenge of Metallo-β-Lactamase Inhibition: Mechanism Matters. , 2018, Trends in pharmacological sciences.

[54]  M. Tolmasky,et al.  Assessment of External Guide Sequences' (EGS) Efficiency as Inducers of RNase P-Mediated Cleavage of mRNA Target Molecules. , 2018, Methods in molecular biology.

[55]  M. Tolmasky,et al.  Internalization of Locked Nucleic Acids/DNA Hybrid Oligomers into Escherichia coli , 2012, BioResearch open access.

[56]  P. Nordmann,et al.  Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) restores carbapenem susceptibility to NDM-1-positive pathogens in vitro and in vivo , 2016, The Journal of antimicrobial chemotherapy.

[57]  Yanhua Rao,et al.  Strategies for controlling CRISPR/Cas9 off-target effects and biological variations in mammalian genome editing experiments. , 2018, Journal of biotechnology.

[58]  A. Jankowska,et al.  Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. , 2011, Blood.

[59]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[60]  Richard S Geary,et al.  Fomivirsen: clinical pharmacology and potential drug interactions. , 2002, Clinical pharmacokinetics.

[61]  A. Fire,et al.  Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[62]  V. Shivarov,et al.  Rapid Detection of DNMT3A R882 Mutations in Hematologic Malignancies Using a Novel Bead-Based Suspension Assay with BNA(NC) Probes , 2014, PloS one.

[63]  K. Mortensen,et al.  Hitting bacteria at the heart of the central dogma: sequence-specific inhibition , 2007, Microbial cell factories.

[64]  L. Aurelian,et al.  An Approach to Chemotherapy Based on Base Sequence Information and Nucleic Acid Chemistry Matagen (Masking Tape for Gene Expression) , 1987, Annals of the New York Academy of Sciences.

[65]  Ajay Jain,et al.  CRISPR-Cas9 directed genome engineering for enhancing salt stress tolerance in rice. , 2019, Seminars in cell & developmental biology.

[66]  M. Tolmasky,et al.  Inhibition of aac(6′)-Ib-mediated amikacin resistance by nuclease-resistant external guide sequences in bacteria , 2009, Proceedings of the National Academy of Sciences.

[67]  M. Cazzola,et al.  Mutations and prognosis in primary myelofibrosis , 2013, Leukemia.

[68]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[69]  H. Soifer,et al.  Silencing of gene expression by gymnotic delivery of antisense oligonucleotides. , 2012, Methods in molecular biology.

[70]  Jason D. Kahn,et al.  Position-dependent effects of locked nucleic acid (LNA) on DNA sequencing and PCR primers , 2006, Nucleic acids research.

[71]  S. Maiti,et al.  Perspectives on chemistry and therapeutic applications of Locked Nucleic Acid (LNA). , 2007, Chemical reviews.

[72]  Neeraj Shah,et al.  PCSK9 inhibitors: A new era of lipid lowering therapy , 2017, World journal of cardiology.

[73]  D. Corey,et al.  Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. , 2001, Chemistry & biology.

[74]  J. Joung,et al.  High-fidelity CRISPR-Cas9 variants with undetectable genome-wide off-targets , 2015, Nature.

[75]  J. Wengel,et al.  Synthesis of Novel Bicyclo[2.2.1] Ribonucleosides: 2'-Amino- and 2'-Thio-LNA Monomeric Nucleosides. , 1998, The Journal of organic chemistry.

[76]  F. Eckstein,et al.  Nucleoside phosphorothioates. , 1970, Journal of the American Chemical Society.

[77]  M. Goodell,et al.  DNMT3A in Leukemia. , 2017, Cold Spring Harbor perspectives in medicine.

[78]  S. Miyano,et al.  Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients , 2014, Leukemia.

[79]  J. Stenvang,et al.  The utility of LNA in microRNA-based cancer diagnostics and therapeutics. , 2008, Seminars in cancer biology.

[80]  P. Nielsen,et al.  Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA , 1998, Nature Biotechnology.

[81]  P. Hsu,et al.  Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity. , 2016, Molecular cell.

[82]  J. Wengel,et al.  Locked Nucleic Acids: Promising Nucleic Acid Analogs for Therapeutic Applications , 2010, Chemistry & biodiversity.

[83]  A. Probst,et al.  High-Affinity LNA-DNA Mixmer Probes for Detection of Chromosome-Specific Polymorphisms of 5S rDNA Repeats in Arabidopsis thaliana. , 2018, Methods in molecular biology.

[84]  M. Guérard,et al.  Locked nucleic acid (LNA)‐based single‐stranded oligonucleotides are not genotoxic , 2017, Environmental and molecular mutagenesis.

[85]  R. Bonomo,et al.  External guide sequence technology: a path to development of novel antimicrobial therapeutics , 2015, Annals of the New York Academy of Sciences.

[86]  C. Thornton Myotonic dystrophy. , 2014, Neurologic clinics.

[87]  K. Rye,et al.  Molecular basis of PCSK9 function. , 2009, Atherosclerosis.

[88]  V. Erdmann,et al.  Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA. , 2003, Nucleic acids research.

[89]  T. Ranheim,et al.  Berberine decreases PCSK9 expression in HepG2 cells. , 2008, Atherosclerosis.

[90]  K. Miyashita,et al.  Design, synthesis, and properties of 2',4'-BNA(NC): a bridged nucleic acid analogue. , 2008, Journal of the American Chemical Society.

[91]  E. Kmiec,et al.  Targeted nucleotide exchange in Saccharomyces cerevisiae directed by short oligonucleotides containing locked nucleic acids. , 2002, Chemistry & biology.

[92]  Yan Wang,et al.  A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates , 2009, Proceedings of the National Academy of Sciences.

[93]  S. T. Olalla Saad,et al.  Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis , 2012, PloS one.

[94]  M. Tolmasky,et al.  External Guide Sequences Targeting the aac(6′)-Ib mRNA Induce Inhibition of Amikacin Resistance , 2007, Antimicrobial Agents and Chemotherapy.

[95]  Jennifer A. Doudna,et al.  Conformational control of DNA target cleavage by CRISPR–Cas9 , 2015, Nature.

[96]  A. Prasad,et al.  Nucleic acid therapeutics: basic concepts and recent developments , 2014 .

[97]  J. Wengel,et al.  Novel convenient syntheses of LNA [2.2.1]bicyclo nucleosides , 1998 .

[98]  M. Eickmann,et al.  Anti-Niemann Pick C1 Single-Stranded Oligonucleotides with Locked Nucleic Acids Potently Reduce Ebola Virus Infection In Vitro , 2019, Molecular therapy. Nucleic acids.

[99]  J. Wengel,et al.  Universality of LNA-mediated high-affinity nucleic acid recognition , 1998 .

[100]  M. Tolmasky,et al.  Aminoglycoside modifying enzymes. , 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[101]  Zonghui Yuan,et al.  Bacteria vs. Bacteriophages: Parallel Evolution of Immune Arsenals , 2016, Front. Microbiol..

[102]  S. Altman,et al.  Inhibition of gene expression by RNase P. , 2010, New biotechnology.

[103]  B. Monia,et al.  Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals , 2006, Nucleic acids research.

[104]  M. Nakamori,et al.  Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s disease , 2019, Scientific Reports.

[105]  C. Nguyen,et al.  Myotonic dystrophy type 1 , 2016, Canadian Medical Association Journal.

[106]  Robert Langer,et al.  Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates , 2008, Proceedings of the National Academy of Sciences.

[107]  K. Miyashita,et al.  2′,4′-BNA NC : A Novel Bridged Nucleic Acid Analogue with Excellent Hybridizing and Nuclease Resistance Profiles , 2007, Nucleosides, nucleotides & nucleic acids.

[108]  T. Yamaoka,et al.  Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice , 2012, Molecular therapy. Nucleic acids.

[109]  S. Vogel,et al.  Mismatch discrimination of lipidated DNA and LNA-probes (LiNAs) in hybridization-controlled liposome assembly. , 2016, Organic & biomolecular chemistry.

[110]  A. Kohlmann,et al.  The molecular profile of adult T‐cell acute lymphoblastic leukemia: Mutations in RUNX1 and DNMT3A are associated with poor prognosis in T‐ALL , 2013, Genes, chromosomes & cancer.

[111]  David A. Scott,et al.  Rationally engineered Cas9 nucleases with improved specificity , 2015, Science.

[112]  Wei-Jia Kong,et al.  Combination of simvastatin with berberine improves the lipid-lowering efficacy. , 2008, Metabolism: clinical and experimental.

[113]  Henriette O'Geen,et al.  A genome-wide analysis of Cas9 binding specificity using ChIP-seq and targeted sequence capture , 2014, bioRxiv.

[114]  K. Pfeffer,et al.  Gymnotic Delivery of LNA Mixmers Targeting Viral SREs Induces HIV-1 mRNA Degradation , 2019, International journal of molecular sciences.

[115]  John J Rossi,et al.  Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[116]  J. Concordet,et al.  Transfection and mutagenesis of target genes in mosquito cells by locked nucleic acid-modified oligonucleotides. , 2010, Journal of visualized experiments : JoVE.

[117]  M. Gulisano,et al.  EMX1 homeoprotein is expressed in cell nuclei of the developing cerebral cortex and in the axons of the olfactory sensory neurons , 1996, Mechanisms of Development.

[118]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[119]  S. Kauppinen,et al.  Treatment of HCV infection by targeting microRNA. , 2013, The New England journal of medicine.

[120]  Patrick Castro,et al.  Bridged Nucleic Acids (BNAs) as Molecular Tools , 2015 .

[121]  S. Mayor,et al.  Molecules, mechanisms, and cellular roles of clathrin-independent endocytosis. , 2010, Current opinion in cell biology.

[122]  A. Jeltsch,et al.  Oligomerization and Binding of the Dnmt3a DNA Methyltransferase to Parallel DNA Molecules , 2011, The Journal of Biological Chemistry.

[123]  P. Fenaux,et al.  Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes. , 2013, Best practice & research. Clinical haematology.

[124]  P. Forterre,et al.  History of CRISPR-Cas from Encounter with a Mysterious Repeated Sequence to Genome Editing Technology , 2018, Journal of bacteriology.

[125]  Ryan L Setten,et al.  The current state and future directions of RNAi-based therapeutics , 2019, Nature Reviews Drug Discovery.

[126]  David C. Ream,et al.  Draft Genome of the Multidrug-Resistant Acinetobacter baumannii Strain A155 Clinical Isolate , 2015, Genome Announcements.

[127]  N. Sugimoto,et al.  Effect of locked nucleic acid modifications on the thermal stability of noncanonical DNA structure. , 2011, Biochemistry.

[128]  I. Nabi,et al.  Lipid rafts, caveolae, and their endocytosis. , 2010, International review of cell and molecular biology.

[129]  S. Srivastava,et al.  CRISPR-Cas9: A multifaceted therapeutic strategy for cancer treatment. , 2019, Seminars in cell & developmental biology.

[130]  E. Boerwinkle,et al.  Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study). , 2007, The American journal of cardiology.

[131]  S. Mobashery,et al.  Versatility of Aminoglycosides and Prospects for Their Future , 2003, Clinical Microbiology Reviews.

[132]  D. Corey,et al.  Recognition of chromosomal DNA inside cells by locked nucleic acids. , 2008, Biochemistry.

[133]  P. Iversen Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. , 2001, Current opinion in molecular therapeutics.

[134]  K. Miyashita,et al.  N-Methyl substituted 2',4'- BNANC: a highly nuclease-resistant nucleic acid analogue with high-affinity RNA selective hybridization. , 2007, Chemical communications.

[135]  R. Hartmann,et al.  Locked Nucleic Acid Oligonucleotides , 2012, BioDrugs.

[136]  Zhi-Sheng Jiang,et al.  PCSK9: A new participant in lipophagy in regulating atherosclerosis? , 2019, Clinica chimica acta; international journal of clinical chemistry.

[137]  J. Wengel,et al.  Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2'-O-methyl/LNA oligoribonucleotides. , 2001, Biochemistry.

[138]  Neville E Sanjana,et al.  Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening , 2016, Nature Protocols.

[139]  Y. Hari,et al.  Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2'-O,4'- C-methyleneribonucleosides , 1998 .

[140]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.

[141]  H. Kantarjian,et al.  Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring , 2014, Haematologica.

[142]  C. Bennett,et al.  RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. , 2010, Annual review of pharmacology and toxicology.

[143]  Y. Hari,et al.  Effective syntheses of 2',4'-BNANC monomers bearing adenine, guanine, thymine, and 5-methylcytosine, and the properties of oligonucleotides fully modified with 2',4'-BNANC. , 2019, Bioorganic & medicinal chemistry.

[144]  R. Hartmann,et al.  Locked nucleic acid oligonucleotides: the next generation of antisense agents? , 2007, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[145]  C. Amemiya,et al.  Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. , 1992, Science.

[146]  R. Greil,et al.  Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). , 2013, Blood.

[147]  M. Koizumi,et al.  Synthesis of ENA Nucleotides and ENA Oligonucleotides , 2018, Current protocols in nucleic acid chemistry.

[148]  Jennifer A. Doudna,et al.  Biology and Applications of CRISPR Systems: Harnessing Nature’s Toolbox for Genome Engineering , 2016, Cell.

[149]  R. Juliano,et al.  The delivery of therapeutic oligonucleotides , 2016, Nucleic acids research.

[150]  M. Tolmasky,et al.  Inhibition of AAC(6′)-Ib-Mediated Resistance to Amikacin in Acinetobacter baumannii by an Antisense Peptide-Conjugated 2′,4′-Bridged Nucleic Acid-NC-DNA Hybrid Oligomer , 2015, Antimicrobial Agents and Chemotherapy.

[151]  J. Wengel,et al.  Improved RE31 Analogues Containing Modified Nucleic Acid Monomers: Thermodynamic, Structural, and Biological Effects. , 2019, Journal of medicinal chemistry.

[152]  J. Wengel,et al.  LNA (Locked Nucleic Acid): An RNA Mimic Forming Exceedingly Stable LNA:LNA Duplexes , 1998 .

[153]  Peter C. Fineran,et al.  Remarkable Mechanisms in Microbes to Resist Phage Infections. , 2014, Annual review of virology.

[154]  S. Kauppinen,et al.  Development of microRNA therapeutics is coming of age , 2014, EMBO molecular medicine.

[155]  B. Monia,et al.  Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice Published, JLR Papers in Press, January 22, 2007. , 2007, Journal of Lipid Research.

[156]  P. Iversen,et al.  Cationic phosphorodiamidate morpholino oligomers efficiently prevent growth of Escherichia coli in vitro and in vivo. , 2010, The Journal of antimicrobial chemotherapy.

[157]  Daniel S. Chertow,et al.  CRISPR-Cas Biology and Its Application to Infectious Diseases , 2018, Journal of Clinical Microbiology.

[158]  Vanja Tadić,et al.  CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity. , 2019, Methods.

[159]  L. Johannes,et al.  Current Challenges in Delivery and Cytosolic Translocation of Therapeutic RNAs , 2018, Nucleic acid therapeutics.

[160]  T. Sixma,et al.  LNA modification of single-stranded DNA oligonucleotides allows subtle gene modification in mismatch-repair-proficient cells , 2016, Proceedings of the National Academy of Sciences.

[161]  M. Tolmasky,et al.  Inhibition of Aminoglycoside 6′-N-Acetyltransferase Type Ib-Mediated Amikacin Resistance by Antisense Oligodeoxynucleotides , 2003, Antimicrobial Agents and Chemotherapy.

[162]  S. Kauppinen,et al.  LNA-mediated microRNA silencing in non-human primates , 2008, Nature.

[163]  H. Scher,et al.  First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer , 2013, British Journal of Cancer.

[164]  K. Yusa,et al.  Genome-wide CRISPR-Cas9 screening in mammalian cells. , 2019, Methods.

[165]  Simon W. Jones,et al.  RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA. , 2007, Blood cells, molecules & diseases.

[166]  Emmanuelle Charpentier,et al.  CRISPR-Cas: biology, mechanisms and relevance , 2016, Philosophical Transactions of the Royal Society B: Biological Sciences.

[167]  L. Frost,et al.  F conjugation: back to the beginning. , 2013, Plasmid.

[168]  C. Ducho,et al.  Oligonucleotide analogues with cationic backbone linkages , 2018, Beilstein journal of organic chemistry.

[169]  M. Rauh,et al.  Targeted, Amplicon-Based, Next-Generation Sequencing to Detect Age-Related Clonal Hematopoiesis. , 2019, Methods in molecular biology.

[170]  M. Damha,et al.  Extensive CRISPR RNA modification reveals chemical compatibility and structure-activity relationships for Cas9 biochemical activity , 2018, Nucleic acids research.

[171]  A. Mishra,et al.  Peptide nucleic acids: Advanced tools for biomedical applications , 2017, Journal of Biotechnology.

[172]  R. Gueorguieva,et al.  DNMT3A mutation is a poor prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients. , 2013, Leukemia research.

[173]  S. Crooke,et al.  RNA-Targeted Therapeutics. , 2018, Cell metabolism.

[174]  A Mukherjee,et al.  Nucleic acid aptamers: clinical applications and promising new horizons. , 2011, Current medicinal chemistry.

[175]  David R. Liu,et al.  Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification , 2014, Nature Biotechnology.